Viking Therapeutics
VKTX
193 hedge funds and large institutions have $1.21B invested in Viking Therapeutics in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 65 increasing their positions, 50 reducing their positions, and 42 closing their positions.
101% more call options, than puts
Call options by funds: $95.3M | Put options by funds: $47.3M
30% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 50
21% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 42
10% more capital invested
Capital invested by funds: $1.11B → $1.21B (+$105M)
5% more funds holding
Funds holding: 184 → 193 (+9)
9.84% less ownership
Funds ownership: 84.75% → 74.91% (-9.8%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$102M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$84.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$61.8M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$33.3M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$28.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$42.2M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$32.4M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26.1M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$17.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.5M |
VKTX Hedge Fund Activity: Q2 2023 in Review
193 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2023, worth a combined $1.21B — up 9.5% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new VKTX positions and 42 closed out — a net gain of 9 holders — while 65 added to existing stakes and 50 trimmed.
The largest buyer was BlackRock, adding an estimated $102M. The largest seller was Millennium Management, cutting an estimated $42.2M.
- 193 institutional investors held Viking Therapeutics (VKTX) as of Q2 2023, up from 184 in Q1 2023.
- Funds reported $1.21B of Viking Therapeutics stock for Q2 2023, up 9.5% quarter-over-quarter.
- 51 funds opened new Viking Therapeutics positions in Q2 2023 and 42 closed out, a net change of +9 holders.
- The largest Viking Therapeutics buyer in Q2 2023 was BlackRock, an estimated $102M added.
- The largest Viking Therapeutics seller in Q2 2023 was Millennium Management, an estimated $42.2M sold.
Based on aggregated 13F filings for Q2 2023.